tellmegen logo

Susceptibility and evolution of COVID-19 disease study


tellmeGen, in association with the Institute of Immunology, University Medicine in Rostock (Germany), led by Prof. Dr. med. habil. Hans-Juergen Thiesen, starts a pioneering genetic study related to the susceptibility to SARS-CoV2 infections and its subsequent COVID-19 disease.

Our goal is focused on identifying predictive epi-/genetic markers that identify people at risk of suffering from severe COVID-19 disease, regardless of age, sex, viral load and comorbidities.

Therefore, we are going to split patients with a positive diagnosis of COVID-19 into the following strata:

Group I: SARS-CoV2 positive without hospital admission (asymptomatic or mild symptoms).

Group II: SARS-CoV2 positive with hospital admission (supplemental oxygen measures).

Group III: SARS-CoV2 positive with admission to the Intensive Care Unit (ICU) (need for assisted breathing).

We invite each individual who experienced SARS-CoV2 infections to contact us.

For further information, please contact us at:
[email protected]